



EC Certificate Full Quality Assurance System: Certificate KR19/81826209

The management system of

DAESUNG MAREF CO., LTD.

(HQ & 1st Factory) 298-24, Gongdan-ro, Gunpo-si, Gyeonggi-do, Korea

has been assessed and certified as meeting the requirements of

Directive 93/42/EEC on medical devices, Annex II (excluding Section 4)

For the following products

The scope of registration appears on page 2 of this certificate.

This certificate is valid from 05 November 2020 until 10 July 2023
and remains valid subject to satisfactory surveillance audits.

Issue 3. Certified since 10 July 2015
and first certified by SGS Belgium NV since 16 December 2019

This is a multi-site certification.
Additional site details are listed on subsequent pages

Certification is based on reports numbered KR/SEL Y-PC/14403

Authorised by

SGS Belgium NV, Notified Body 1639

SGS House Noorderlaan 87 2030 Antwerp Belgium
t +32 (0)3 545-48-48 f +32 (0)3 545-48-49 www.sgs.com

LPMD5007 - Certificate CE1639 Annex II-4_EN rev. 02

Page 1 of 2



This document is issued by the Company subject to its General Conditions of Certification Services, unless otherwise agreed, accessible at www.sgs.com/terms_and_conditions.htm. Attention is drawn to the limitations of liability, indemnification and jurisdictional issues established therein. The authenticity of this document may be verified at <https://www.sgs.com/en/certified-clients-and-products/certified-client-directory>. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.

DAESUNG MAREF CO., LTD.

Directive 93/42/EEC on medical devices, Annex II (excluding Section 4)

Issue 3

Detailed scope

**Intermittent Pneumatic Compression System for the treatment
and prevention of lymphedema (Model: LF900, MK400L);**

**Digital Pneumatic Tourniquet System for the hemostasis
during surgery (Model: DTS-3000);**

**Intermittent Pneumatic Compression System for the prevention
of deep vein thrombosis and pulmonary embolism after surgery
(Model: DVT-2600, DVT-4000S, DVT-PRO)**

Where the above scope includes class III medical device(s), a valid EC Design Examination Certificate according to Annex II (Section 4) is a mandatory requirement for each device in addition to this certificate to place that device on the market.

Additional facilities

**(Warehouse) 25-22, Hyundaiakia-ro,
Paltan-myeon, Hwaseong-si, Gyeonggi-do, Korea
(2nd Factory) 1F, 298-21, Gongdan-ro, Gunpo-si, Gyeonggi-do, Korea**

DAESUNG MAREF CO., LTD.

(HQ & 1st Factory) 298-24, Gongdan-ro, Gunpo-si, Gyeonggi-do, Korea

Scope:

Intermittent Pneumatic Compression System for the treatment and prevention of lymphedema (Model: LF900, MK400L);

Digital Pneumatic Tourniquet System for the hemostasis during surgery (Model: DTS-3000);

Intermittent Pneumatic Compression System for the prevention of deep vein thrombosis and pulmonary embolism after surgery (Model: DVT-2600, DVT-4000S, DVT-PRO)

This corrigendum is only valid together with accompanying 93/42/EEC certificate Issue 3

<u>Correction Date</u>	<u>Correction</u>
Change approved by SGS on 05 December 2022	Removal the device 'Digital Pneumatic Tourniquet System for the hemostasis during surgery (Model: DTS-3000)' in MDD scope

Authorised by

Global Medical Devices Certification Manager

SGS Belgium NV, Notified Body 1639

SGS House Noorderlaan 87 2030 Antwerp Belgium
t +32 (0)3 545 48 48 f +32 (0)3 545 48 49 www.sgs.com

LPMD5105 – Corrigendum to Certificate

Page 1 of 1

SGS Belgium NV

Certification and Business Enhancement Maatschappelijke Zetel/Siège Social:
Noorderlaan 87 B-2030 Antwerpen/Anvers
t +32 (0)3 545 48 48 f +32 (0)3 545 48 49
www.be.sgs.com

Member of the SGS Group

RPR Antwerp VAT – BE 0404.882.750 Citibank BE87 5701 3412 5594

DAESUNG MAREF CO., LTD

(Head Office & 1st Factory) 298-24, Gongdan-ro, Gunpo-si, Gyeonggi-do, 15809, Korea

(Laboratory & A/S Center & 2nd Factory) 1F, 2F, 4F, 298-21, Gongdan-ro, Gunpo-si, Gyeonggi-do, 15809, Korea

(Warehouse) 25-22, Hyundaikia-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do, 18576, Korea

12-July-2023

Confirmation Letter Reference: CLNB1639 – KR/SEL 14403

To whom it may concern,

Confirmation of receipt of a formal application and conclusion of written agreement in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices.

This letter confirms that, SGS Belgium NV, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number 1639 on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer

DAESUNG MAREF CO., LTD

(Head Office & 1st Factory) 298-24, Gongdan-ro, Gunpo-si, Gyeonggi-do, 15809, Korea

(Laboratory & A/S Center & 2nd Factory) 1F, 2F, 4F, 298-21, Gongdan-ro, Gunpo-si, Gyeonggi-do, 15809, Korea

(Warehouse) 25-22, Hyundaikia-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do, 18576, Korea

SRN Number (if available): KR-MF-000008616

Authorized representative

KTR Europe GmbH

Mergenthalerallee 77, Eschborn, 65760, Germany

The devices covered by the formal application and the written agreement mentioned above are shown at the end of this letter.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired prior to the publication of the Regulation EU 2023/607 on 15th March 2023, this letter also confirms that:

- The manufacturer submitted the MDR application and signed the written agreement by the date of MDD/AIMDD certificate expiry;
- The certificates expired after 26th May 2021 by course of time and were valid at the date of their expiry neither having been suspended nor withdrawn.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3 of MDR (as amended by EU 2023/607), are shown below:

- 26th May 2026 for Class III custom-made implantable devices
- 31st December 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- 31st December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- 31st December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of the Notified Body SGS Belgium NV 1639,



Ian How
PP

Virginie SILORET
Global Medical Device Certification Manager
Email: Virginie.siloret@sgs.com
Phone: +41 22 739 98 58

Devices covered by this letter:

Device name / Basic UDI-DI	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
Intermittent Pneumatic Compression System for the prevention of deep vein thrombosis and pulmonary embolism after	Class IIa	N/A	NB1639 KR19/81826209

Device name / Basic UDI-DI	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
surgery (Models: DVT-4000S, DVT-2600) Basic UDI-DI: 880931567DVTSD			
Intermittent Pneumatic Compression System for the treatment and prevention of lymphedema (Model: LF900, MK400L) Basic UDI-DI: 880931567IPCRJ	Class IIa	N/A	NB1639 KR19/81826209

Confirmation Letter Revision History

Date	NB internal reference traceable to each version of the letter	Action
2023/07/12	KR/SEL 14403	Initial issue